Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NX-1607 |
| Synonyms | |
| Therapy Description |
NX-1607 is a small molecule Cblb inhibitor, which potentially enhances antitumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS2691). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NX-1607 | NX1607|NX 1607 | NX-1607 is a small molecule Cblb inhibitor, which potentially enhances antitumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS2691). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05107674 | Phase I | NX-1607 | A Study of NX-1607 in Adults With Advanced Malignancies | Recruiting | USA | GBR | 0 |